The University of Manchester’s Intellectual Property Commercialisation Company, UMIP Ltd, has won the Business Impact category at the Unico Awards which recognise and celebrate the impact of innovation.
UMIP was recognised by the judges for its spin-out company Transitive, which was acquired in November last year by IBM. Transitive’s technology allows the transportability of software applications across multiple hardware platforms with little or no modification. Today, Transitive products are installed on over 20M computers world-wide.
Unico is the UK’s leading knowledge transfer membership association and UMIP’s Dr Rich Ferrie picked up the Business Impact Award at the Association’s Gala Dinner at Brighton Racecourse in June.
The Impact Awards were open to all sectors of research that have made an outstanding impact through successful knowledge transfer. Awards were also made for a series of novel innovations in two other award categories: Environmental Impact and Public Policy and Service Impact. They recognise and celebrate the success of collaborative working and the process of transferring knowledge and expertise from the research base of higher education and the public sector for the wider benefit of society and the economy.
Commenting on the award, UMIP’s CEO, Clive Rowland, said: “Transitive is the latest of The University of Manchester’s notable commercialisation success stories and it is great for Transitive and UMIP to receive this level of recognition.“
For more information on The Impact Awards visit www.impactawards.org.uk.
Nanoco Group PLC began trading on the London Stock Exchange AIM Market at 0800 GMT, Friday, 1st May under the ticker symbol “NANO”. Shares have traded up over the first few days with the company now valued at greater than £90m. The commencement of trading represents Nanoco’s successful conclusion of the reverse takeover which was announced in late February 2009.
+44 (0) 161 831 1512
Nanoco Group plc:
+44 (0) 161 603 7900
Nanoco is a leading nanotechnology company involved in the development and manufacture of fluorescent semi-conducting materials called quantum dots (QDs).
QDs are a platform technology with wide-ranging applications across several industry sectors from solid state lighting, solar energy and next generation displays to life sciences. Applications based on QD materials have the potential to offer significant improvements over materials traditionally used, giving benefits to performance and energy savings.
Zeus Capital, the Manchester based investment bank, is Nominated Adviser and Broker to Nanoco Group PLC. Nanoco’s chief executive Dr Michael Edelman said: “This listing represents the next milestone in Nanoco’s rapid development.”
“Trading on the AIM Market of the London Stock Exchange allows Nanoco to continue to further strengthen its shareholder base and balance sheet, providing the resources needed to meet the growing demand for its products.”
Nanoco was founded in 2001 by two academics from Manchester University – Professor Paul O’Brien and Dr Nigel Pickett – to advance the development of quantum dots.
“Nanoco’s successful growth”, says Dr Michael Edelman, “is based on focusing our efforts on the development and mass production of high performance quantum dots and partnering with strategic quantum dot application developers around the world to get these exciting materials into the market.”
The Nanoco Group PLC business strategy is to work in partnership with quantum dot application developers. These application developers tend to be large global technology companies working to incorporate quantum dots into a specific end use application such as LEDs, solar cells and displays.
For further enquires please contact:
Nanoco Group PLC, Manchester, UK (www.nanocotechnologies.com);
7th May 2009
The University of Manchester and its intellectual property commercialisation company (UMIP) has signed an agreement with the Johnson & Johnson Corporate Office of Science and Technology (COSAT) to establish a proof-of-principle (PoP) Fund.
COSAT was established in 1978 to foster a long-standing focus on innovation and entrepreneurship by supporting and creating access to breakthrough science and technologies.
The Fund will allow scientists at the University to submit ideas with the promise of having a positive impact on human health. It will lead to projects that explore how new technological approaches, such as regenerative medicine, will impact the treatment of such chronic conditions as Alzheimer’s and diabetes as well as to the generation of new diagnostic markers and medical devices and materials which may help manage disease and wellness.
Successful projects could, post proof-of-principle and further development, be taken to market. This augments the University’s capability for funding innovative projects beyond spin-outs, which is already underpinned by the UMIP Premier Find (UPF).
Professor Rod Coombs, Vice-President for Innovation and Economic Development at The University of Manchester, said: “This fund will prove invaluable for scientists as they look to take their research to new levels and could lead to new technology platforms which will underpin new therapies. We are delighted that COSAT has chosen Manchester as a centre of excellence.”
Clive Rowland, Chief Executive Officer of UMIP, said: “This agreement will allow scientists to make major strides forward in their research as well as help them to develop that research into products with commercial potential. UMIP will make decisions on how to distribute the fund, based on the commercial case of each individual submission.”
Joe Smith, COSAT, and Prof Rod Coombs
The University of Manchester’s graduate internship programme is the flexible, cost effective way to solve your recruitment needs.
Highly skilled graduates are available for short term Internships of between 4 – 12 months giving businesses the opportunity to buy-in the skills and talent required without entering into permanent employment contracts.
The Manchester Graduate Internship Programme (MGIP) is also the cost effective way to find, recruit and cultivate talented staff. With average salaries of around £14,000 for a typical 12 month internship the MGIP programme gives added value where businesses need it most. In addition the MGIP Team takes the hassle out of the recruitment process by offering businesses advice and guidance all through the recruitment process. We’ll even shortlist and help with the Interviews!
Building great teams is never easy but the Internships programme helps you to access intelligent, articulate, determined and enthusiastic graduates all of whom have expressed an interest in starting their career in Manchester working with organisations like yours.
Don’t let market conditions stop your business from growing. Recruit an Intern today!
Contact the MGIP team on 0161 275 4041 or visit the website www.careers.manchester.ac.uk/internships
The University of Manchester spin-out company Photo Therapeutics has been acquired for $20M by the US-listed company PhotoMedex. Photo Therapeutics (PTL), established in the late 1990s, is based on patented technology developed by Colin Whitehurst, a researcher at The University of Manchester’s Paterson Institute for Cancer Research, with funding from Cancer Research UK., CEO of UMIP said: “Both companies are at the leading edge of new technological developments in extremely important therapeutic areas such as cancer and dermatology. Their international recognition is a great success for The University and for the world-leading cancer research and care organisations in Manchester like The Paterson Institute and The Christie which all work in partnership with Cancer Research UK in the Manchester Cancer Research Centre.”
Assistance with the formation and development of the company was provided by The University of Manchester’s Intellectual Property commercialisation company, UMIP and Cancer Research Technology.
Photo Therapeutics develops non-laser light devices and associated skin care products for the treatment of a range of clinical and aesthetic dermatological conditions. The company’s systems treat a wide range of conditions including acne, photodamage, skin rejuvenation, psoriasis, post-surgery wound healing and non-melanoma skin cancer.
PhotoMedex is the leader in the development, manufacturing and marketing of medical laser products and services across multiple specialty areas, including dermatology, urology, gynaecology, orthopaedics and other surgical specialties.
Sue D’Arcy, CEO of Photo Therapeutics, said: “We are all excited about the acquisition, it gives Photo Therapeutics the opportunity to leverage the direct sales force that PhotoMedex Inc has in the States and move to the next level with this great technology.”News of the acquisition comes a week after Epistem announced its $4m R&D collaboration with Novartis. Epistem was also spun out from the Paterson Institute.